No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Trastuzumab emtansine monotherapy is noninferior to standard neoadjuvant therapy for ERBB2+ breast cancer

byTeddy Guo

September 8, 2021

in StudyGraphics

Reading Time: 1 min read

#VisualAbstract: Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa

RelatedReports

StudyGraphics

#VisualAbstract: Elinzanetant Effectively Reduces Vasomotor Symptoms from Endocrine Therapy for Breast Cancer

June 17, 2025

Pharma

2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]

June 4, 2025

Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs

Gastroenterology

Sotorasib plus panitumumab may be a promising treatment option for colorectal cancer

April 16, 2025

One-year of Herceptin preferable to two-year regimen

Oncology

Imlunestrant extends progression-free survival in ER-positive, HER2-negative breast cancer

April 11, 2025

Updated USPSTF guidelines favor treatment of mild gestational diabetes

Novel macrophage-regulating cream demonstrated superior therapeutic efficacy for the treatment of diabetic foot ulcers compared to standard absorbent dressing

$The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor$

Biologic teclistamab shows promise in treatment of refractory multiple myeloma in phase 1 drug study

Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation

Association of sleep duration with all-cause mortality in East Asian adults

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports